Biopsy of Bladder

PROCEDURE3 trials

Sponsors

National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology

Conditions

Bladder Urothelial CarcinomaMuscle Invasive Bladder CarcinomaRecurrent Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8Stage II Bladder Cancer AJCC v8Stage III Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Phase 2

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Active, not recruitingNCT04216290

National Cancer Institute (NCI)Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8

Start: 2021-03-17End: 2026-06-30Target: 95Updated: 2025-11-12

Phase 3

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Active, not recruitingNCT03775265

National Cancer Institute (NCI)Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8 +1

Start: 2019-06-03End: 2027-06-01Target: 475Updated: 2026-04-03

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

RecruitingNCT07000084

Alliance for Clinical Trials in OncologyRecurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8

Start: 2025-07-17End: 2028-12-05Target: 330Updated: 2026-03-04

Related Papers

Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)

Journal for ImmunoTherapy of Cancer2025-03-013 citations

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

Journal for ImmunoTherapy of Cancer2023-02-0126 citations

Healthcare provider evaluation of machine learning-directed care: reactions to deployment on a randomised controlled study

BMJ Health & Care Informatics2023-02-015 citations

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

Journal of Clinical Oncology2022-06-012 citations

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

Journal of Clinical Oncology2022-02-16

Machine Learning Algorithm Prospectively Predicts Survival for High-Risk Patients Undergoing Radiotherapy: A Survival Analysis of SHIELD-RT.

2021-11-011 citations

Impact of machine learning-directed on-treatment evaluations on cost of acute care visits: Economic analysis of SHIELD-RT.

Journal of Clinical Oncology2021-05-202 citations

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE)—An ECOG-ACRIN and NRG Collaboration.

Journal of Clinical Oncology2021-05-20

INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.

Journal of Clinical Oncology2021-02-2026 citations

EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration.

Journal of Clinical Oncology2021-02-204 citations

INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806.

Journal of Clinical Oncology2020-02-1916 citations

Precision Medicine in Bladder Cancer

Oncology Times2019-05-31